ReviewThe European respiratory journal2024
Pulmonary hypertension associated with left heart disease.
Review in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07082400 (Screening and Phenotyping of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction .), which is not on this map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Screening and Phenotyping of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction .
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brazilian guidelines for the pharmacological treatment of pulmonary hypertension. Official document of the Brazilian Thoracic Society based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.Respiratory research & clinical practice · 2026Guideline
- Sotatercept in Pulmonary Arterial Hypertension: Central, Hematologic, and Peripheral Mechanisms of Benefit.Journal of the American College of Cardiology · 2026Trial
- Fatty Acid and Oxylipin Metabolism Differentiate Isolated Postcapillary From Combined Pre- and Postcapillary Pulmonary Hypertension.Circulation. Heart failure · 2026Article
- Phenotypes, periprocedural hemodynamic changes, and impact of pulmonary hypertension in patients undergoing mitral transcatheter edge-to-edge repair.Cardiovascular intervention and therapeutics · 2026Article
- The Electrocardiogram and Pulmonary Hypertension: When Occam'S Razor Fails.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- The Epidemiology of Pulmonary Hypertension in Sub-Saharan Africa-A Systematic Report.Pulmonary circulation · 2026Article
- Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review.Pulmonary circulation · 2026Review
- Evolution of Exercise Training in Patients with Pulmonary Hypertension-A Comprehensive Review.Healthcare (Basel, Switzerland) · 2026Review
- Explainable Lightweight AI for the Identification of Right-Sided Cardiac Dysfunction in a Saudi Arabian Diabetic Cohort.Journal of clinical medicine · 2026Article
- Heart-Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction.Comprehensive physiology · 2026Review
- Clinical Updates in Pulmonary Hypertension.Reviews in cardiovascular medicine · 2026Review
- Digital Data Collection Reduces Terminal Digit Bias in Haemodynamic and Physical Activity Measures in Pulmonary Arterial Hypertension.Pulmonary circulation · 2026Article
- National Patterns of Pulmonary Hypertension Mortality in the United States, 2010 to 2024.The American journal of cardiology · 2026Article
- Conceptual Reconsideration of the Classification of Pulmonary Hypertension: From 5 Groups to 2 Groups.JACC. Asia · 2026Review
- You Can't Always Get What You Want: Sensitivity or Specificity in Pulmonary Hypertension Prediction.JACC. Asia · 2026Article
- A hemodynamic and biomarker study of pulmonary hypertension associated with heart failure: DISCOVER PH-HF.Journal of cardiovascular medicine (Hagerstown, Md.) · 2026Article
- Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension.ERJ open research · 2026Review
- Diagnostic and management dilemmas in pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- One Health Insights into Pulmonary Hypertension: Bridging Human and Canine Medicine.Veterinary sciences · 2026Review
- Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Left heart disease (LHD) is the most common cause of pulmonary hypertension (PH), which may be classified further as isolated post-capillary (ipcPH) or combined post- and pre-capillary PH (cpcPH). The 7th World Symposium on Pulmonary Hypertension PH-LHD task force reviewed newly reported randomised clinical trials and contemplated novel opportunities for improving outcome. Results from major randomised clinical trials reinforced prior recommendations against the use of pulmonary arterial hypertension therapy in PH-LHD outside of clinical trials, and suggested possible harm. Greater focus on phenotyping was viewed as one general strategy by which to ultimately improve clinical outcomes. This is potentially achievable by individualising ipcPH
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.